KA/EN
Register
Medicines reference
Search
Search
Active substance

Eprinomectin

Favourites

Macrocyclic lactone (avermectin). Registered in Georgia: 2 veterinary products. Forms: spot-on.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Eprinomectin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.48 mg/kg Cat Maintenance On the skin once
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
NexGard Combo spot-on solution for cats 2.5-7.5 kg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
Before use

Safety information

Known Contraindications

  • Critical
    Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
    Sources: VMD SPC · VMD
  • Warning (Cat)
    The safety of the veterinary medicinal product has not been tested in kittens under 8 weeks of age. The product is for use in cats weighing at least 0.8 kg and from 8 weeks of age.
    Sources: VMD SPC · VMD
  • Warning (Cat)
    Target animal safety has not been evaluated beyond 6 consecutive monthly treatments and accumulation of esafoxolaner and eprinomectin was observed up to the 5th monthly administration (see also sections 3.10 and 4.3). Repeated treatments beyond 6 consecutive months should be restricted to limited individual situations (see section 3.9 for treatment guidance), with a minimum treatment interval of 4 weeks, according to a benefit-risk evaluation by the responsible veterinarian.
    Sources: VMD SPC · VMD
  • Caution (Cat)
    Although the veterinary medicinal product may be safely administered to cats infected with adult heartworms, no therapeutic effect against adult Dirofilaria immitis has been established. It is, therefore, recommended that all cats 6 months of age or older, living in endemic areas for heartworm, should be tested for existing adult heartworm infection before being treated with the product for heartworm disease prevention.
    Sources: VMD SPC · VMD
Latin name
Eprinomectin
Georgian name
ეპრინომექტინი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
2 of 4 forms
Products
Broadline, NexGard Combo
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration4

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Broadline, Spot-on

fipronil 24.9 mg + (S)-methoprene 30.0 mg + eprinomectin 1.20 mg + praziquantel 24.9 mg, spot-on solution for cats <2.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.3/10
Very good
vetman assessment

Broadline

fipronil 24.9 mg + (S)-methoprene 30.0 mg + eprinomectin 1.20 mg + praziquantel 24.9 mg, spot-on solution for cats <2.5 kg
Assessed clinical scopeCat · Full feline EU label when ectoparasites, nematodes and cestodes are all targeted: fleas/FAD, Ixodes ricinus, Notoedres cati, listed tapeworms, gastrointestinal, lung and vesical worms, and heartworm prevention · On the skin
Care settingVeterinary-prescribed feline multiparasite treatment after individual clinical, lifestyle and epidemiological assessment
vetman score 8.3/10 Very good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A highly effective, unusually broad feline endectoparasiticide when all three parasite groups genuinely need concurrent treatment. Its strong EU evidence does not change its absence from the Georgian register, and broad coverage should not replace narrower first-line therapy when mixed risk is absent.

Regulatory and scientific credibility8.2/10

The exact presentation has a valid central EU authorisation and a current UPD record, supported by detailed official product information and a mature EPAR. It is not registered in Georgia or the US; the separate GB national authorisation expired on 3 July 2026, while EU authorisation including Northern Ireland remains valid.

Clinical efficacy9.0/10

Controlled and multicentre field evidence supports high activity across fleas, major gastrointestinal helminths, lungworms, eyeworm and heartworm prevention. The label is deliberately restricted to simultaneous three-group need; tick protection is shorter than flea protection, and some parasite-specific follow-up or repeat dosing remains necessary.

Safety and tolerability7.5/10

Correct topical use is generally well tolerated and has a wide experimental safety margin, but common local coat or skin changes and salivation can occur. Accidental licking can cause gastrointestinal or transient neurological signs; very rare tremor or visual impairment, reproductive uncertainty and important species and health restrictions require counselling.

Clinical practicality8.4/10

One whole applicator gives broad single-dose coverage and is easier than several separate products, but it must reach the skin at an inaccessible neck site, the cat must not be bathed for two days, exact weight-band selection is required and cats above 7.5 kg need a veterinarian-selected applicator combination.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in sick or convalescent animals, rabbits, or with hypersensitivity to an ingredient. This feline product is not intended for dogs; prevent oral exposure, especially in Collies, Old English Sheepdogs and related breeds.
  • Do not use below 0.6 kg or under 7 weeks of age. Safety in pregnancy and lactation is not established; use only after veterinary benefit-risk assessment. Safety at intervals shorter than two weeks has not been tested.
  • Counsel for common transient coat clumping, local itching or hair loss and salivation. Accidental licking can cause vomiting, hypersalivation, ataxia, disorientation, apathy or pupil dilation; tremor and transient blindness or impaired vision are very rare. Reassess signs persisting beyond 24 hours.
  • Use only for confirmed mixed infestation or substantial concurrent risk involving ectoparasites, nematodes and cestodes. If three-group risk is absent, choose a narrower first-line parasiticide; avoid unnecessary frequent use and underdosing that can select resistance.
  • Flea treatment and environmental-stage control last at least one month, while Ixodes ricinus protection lasts up to three weeks. Tick attachment and pathogen transmission cannot be completely excluded; treat household animals and the environment when clinically indicated.
  • For heartworm prevention, test cats aged at least 6 months in endemic areas because adult Dirofilaria is not treated. Aelurostrongylus may need a second dose after one month; Joyeuxiella needs post-treatment follow-up, and tapeworm control requires management of fleas, rodents and other intermediate hosts.
  • Weigh exactly and empty the whole applicator onto visible skin at the midline of the neck where licking is prevented. Use 0.3 ml below 2.5 kg and 0.9 ml at 2.5-7.5 kg; above 7.5 kg use a veterinarian-selected applicator combination. Avoid bathing for two days, wear gloves, limit handling until dry and keep product or containers out of watercourses.
Assessment sources
  1. EU UPD Broadline 0.3 ml2026
  2. EC Broadline product information2021
  3. EMA Broadline EPAR2026
  4. Georgia NFA register 20262026
  5. Broadline European field study2014
  6. Broadline Brazil field study2022
  7. Broadline lungworm field study2015
  8. Broadline Thelazia field trial2021
  9. Broadline heartworm studies2014
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fipronil24.9 mg (S)-Methoprene30 mg Eprinomectin1.2 mg Praziquantel24.9 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Expired
Expired on 03 Jul 2026, not renewed yet
№ 61700/5085
Verified on: 22 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Broadline, Spot-on

fipronil 74.7 mg + (S)-methoprene 90.0 mg + eprinomectin 3.60 mg + praziquantel 74.7 mg, spot-on solution for cats 2.5-7.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.3/10
Very good
vetman assessment

Broadline

fipronil 74.7 mg + (S)-methoprene 90.0 mg + eprinomectin 3.60 mg + praziquantel 74.7 mg, spot-on solution for cats 2.5-7.5 kg
Assessed clinical scopeCat · Full feline EU label when ectoparasites, nematodes and cestodes are all targeted: fleas/FAD, Ixodes ricinus, Notoedres cati, listed tapeworms, gastrointestinal, lung and vesical worms, and heartworm prevention · On the skin
Care settingVeterinary-prescribed feline multiparasite treatment after individual clinical, lifestyle and epidemiological assessment
vetman score 8.3/10 Very good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A highly effective, unusually broad feline endectoparasiticide when all three parasite groups genuinely need concurrent treatment. Its strong EU evidence does not change its absence from the Georgian register, and broad coverage should not replace narrower first-line therapy when mixed risk is absent.

Regulatory and scientific credibility8.2/10

The exact presentation has a valid central EU authorisation and a current UPD record, supported by detailed official product information and a mature EPAR. It is not registered in Georgia or the US; the separate GB national authorisation expired on 3 July 2026, while EU authorisation including Northern Ireland remains valid.

Clinical efficacy9.0/10

Controlled and multicentre field evidence supports high activity across fleas, major gastrointestinal helminths, lungworms, eyeworm and heartworm prevention. The label is deliberately restricted to simultaneous three-group need; tick protection is shorter than flea protection, and some parasite-specific follow-up or repeat dosing remains necessary.

Safety and tolerability7.5/10

Correct topical use is generally well tolerated and has a wide experimental safety margin, but common local coat or skin changes and salivation can occur. Accidental licking can cause gastrointestinal or transient neurological signs; very rare tremor or visual impairment, reproductive uncertainty and important species and health restrictions require counselling.

Clinical practicality8.4/10

One whole applicator gives broad single-dose coverage and is easier than several separate products, but it must reach the skin at an inaccessible neck site, the cat must not be bathed for two days, exact weight-band selection is required and cats above 7.5 kg need a veterinarian-selected applicator combination.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in sick or convalescent animals, rabbits, or with hypersensitivity to an ingredient. This feline product is not intended for dogs; prevent oral exposure, especially in Collies, Old English Sheepdogs and related breeds.
  • Do not use below 0.6 kg or under 7 weeks of age. Safety in pregnancy and lactation is not established; use only after veterinary benefit-risk assessment. Safety at intervals shorter than two weeks has not been tested.
  • Counsel for common transient coat clumping, local itching or hair loss and salivation. Accidental licking can cause vomiting, hypersalivation, ataxia, disorientation, apathy or pupil dilation; tremor and transient blindness or impaired vision are very rare. Reassess signs persisting beyond 24 hours.
  • Use only for confirmed mixed infestation or substantial concurrent risk involving ectoparasites, nematodes and cestodes. If three-group risk is absent, choose a narrower first-line parasiticide; avoid unnecessary frequent use and underdosing that can select resistance.
  • Flea treatment and environmental-stage control last at least one month, while Ixodes ricinus protection lasts up to three weeks. Tick attachment and pathogen transmission cannot be completely excluded; treat household animals and the environment when clinically indicated.
  • For heartworm prevention, test cats aged at least 6 months in endemic areas because adult Dirofilaria is not treated. Aelurostrongylus may need a second dose after one month; Joyeuxiella needs post-treatment follow-up, and tapeworm control requires management of fleas, rodents and other intermediate hosts.
  • Weigh exactly and empty the whole applicator onto visible skin at the midline of the neck where licking is prevented. Use 0.3 ml below 2.5 kg and 0.9 ml at 2.5-7.5 kg; above 7.5 kg use a veterinarian-selected applicator combination. Avoid bathing for two days, wear gloves, limit handling until dry and keep product or containers out of watercourses.
Assessment sources
  1. EU UPD Broadline 0.9 ml2026
  2. EC Broadline product information2021
  3. EMA Broadline EPAR2026
  4. Georgia NFA register 20262026
  5. Broadline European field study2014
  6. Broadline Brazil field study2022
  7. Broadline lungworm field study2015
  8. Broadline Thelazia field trial2021
  9. Broadline heartworm studies2014
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fipronil74.7 mg (S)-Methoprene90 mg Eprinomectin3.6 mg Praziquantel74.7 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Expired
Expired on 03 Jul 2026, not renewed yet
№ 61700/5084
Verified on: 22 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

NexGard Combo, Spot-on

esafoxolaner 3.60 mg + eprinomectin 1.20 mg + praziquantel 24.90 mg, spot-on solution for cats 0.8-<2.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.5/10
Very good
vetman assessment

NexGard Combo

esafoxolaner 3.60 mg + eprinomectin 1.20 mg + praziquantel 24.90 mg, spot-on solution for cats 0.8-<2.5 kg
Assessed clinical scopeCat · Full labelled feline mixed-infestation scope, exclusively when ectoparasites, gastrointestinal nematodes and cestodes are all targeted together, including labelled flea, tick, mite, worm and cardiopulmonary indications · On the skin
Care settingVeterinary-selected integrated feline parasite treatment after diagnosis and exposure-risk assessment
vetman score 8.5/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 77-11, 28-11 · Verified on 15 Oct 2026

A highly effective all-in-one feline option when ectoparasites, nematodes and cestodes must all be targeted; avoid routine use when the full fixed spectrum is unnecessary.

Regulatory and scientific credibility9.5/10

Both exact applicators are centrally authorised in the EU, covered by current official product information and actively registered in Georgia, with a broad indication-specific evidence package.

Clinical efficacy9.0/10

Controlled and field studies support high efficacy against the major labelled ecto- and endoparasites; the benefit depends on selecting a patient in whom all three required parasite groups genuinely need simultaneous treatment.

Safety and tolerability7.0/10

The labelled safety profile is generally favourable, including in pregnancy and lactation, but young or underweight kittens, accumulation with repeated monthly use, rare neurologic toxicity at marked overdose and adult-heartworm assessment require attention.

Clinical practicality8.5/10

One topical applicator treats a very broad mixed infestation and can be used as a single dose, but exact skin placement, prevention of licking, weight-band selection and veterinarian-directed rather than automatic monthly repetition are essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use exclusively when ectoparasites, gastrointestinal nematodes and cestodes are all targeted at the same time; do not use the fixed triple combination for an incomplete target set.
  • Use only from 8 weeks of age and at least 0.8 kg; apply the exact whole applicator to skin where the cat cannot lick it and avoid shampooing for two days.
  • In heartworm-endemic areas, test cats aged 6 months or older for adult infection before prevention; no adulticidal heartworm effect is established.
  • Safety beyond six consecutive monthly treatments has not been evaluated; repeated treatment beyond this is limited to individual benefit-risk decisions with at least four-week intervals.
Assessment sources
  1. VMD SPC 20252025
  2. EMA NexGard Combo EPAR2025
  3. NexGard Combo flea field studies2021
  4. NexGard Combo helminth RCTs2021
  5. NexGard Combo safety studies2021
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Esafoxolaner3.6 mg Eprinomectin1.2 mg Praziquantel24.9 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდ® კომბო დასაწვეთებელი ხსნარი <2.5კგ კატებისათვის
№ 77-11, 28-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-570
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

NexGard Combo, Spot-on

esafoxolaner 10.80 mg + eprinomectin 3.60 mg + praziquantel 74.70 mg, spot-on solution for cats 2.5-<7.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.5/10
Very good
vetman assessment

NexGard Combo

esafoxolaner 10.80 mg + eprinomectin 3.60 mg + praziquantel 74.70 mg, spot-on solution for cats 2.5-<7.5 kg
Assessed clinical scopeCat · Full labelled feline mixed-infestation scope, exclusively when ectoparasites, gastrointestinal nematodes and cestodes are all targeted together, including labelled flea, tick, mite, worm and cardiopulmonary indications · On the skin
Care settingVeterinary-selected integrated feline parasite treatment after diagnosis and exposure-risk assessment
vetman score 8.5/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 5-11 · Verified on 15 Oct 2026

A highly effective all-in-one feline option when ectoparasites, nematodes and cestodes must all be targeted; avoid routine use when the full fixed spectrum is unnecessary.

Regulatory and scientific credibility9.5/10

Both exact applicators are centrally authorised in the EU, covered by current official product information and actively registered in Georgia, with a broad indication-specific evidence package.

Clinical efficacy9.0/10

Controlled and field studies support high efficacy against the major labelled ecto- and endoparasites; the benefit depends on selecting a patient in whom all three required parasite groups genuinely need simultaneous treatment.

Safety and tolerability7.0/10

The labelled safety profile is generally favourable, including in pregnancy and lactation, but young or underweight kittens, accumulation with repeated monthly use, rare neurologic toxicity at marked overdose and adult-heartworm assessment require attention.

Clinical practicality8.5/10

One topical applicator treats a very broad mixed infestation and can be used as a single dose, but exact skin placement, prevention of licking, weight-band selection and veterinarian-directed rather than automatic monthly repetition are essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use exclusively when ectoparasites, gastrointestinal nematodes and cestodes are all targeted at the same time; do not use the fixed triple combination for an incomplete target set.
  • Use only from 8 weeks of age and at least 0.8 kg; apply the exact whole applicator to skin where the cat cannot lick it and avoid shampooing for two days.
  • In heartworm-endemic areas, test cats aged 6 months or older for adult infection before prevention; no adulticidal heartworm effect is established.
  • Safety beyond six consecutive monthly treatments has not been evaluated; repeated treatment beyond this is limited to individual benefit-risk decisions with at least four-week intervals.
Assessment sources
  1. VMD SPC 20252025
  2. EMA NexGard Combo EPAR2025
  3. NexGard Combo flea field studies2021
  4. NexGard Combo helminth RCTs2021
  5. NexGard Combo safety studies2021
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Esafoxolaner10.8 mg Eprinomectin3.6 mg Praziquantel74.7 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Boehringer Ingelheim · Germany
Manufacturer (register)
SCS Boehringer Ingelheim Animal Health France SCS, France
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1636, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდ® კომბო დასაწვეთებელი ხსნარი 2.5-7.5 კგ კატებისათვის
№ 5-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-570
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 22 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗